Aims The introduction of direct oral anticoagulants (DOACs) has broadened the treatment
arsenal for nonvalvular atrial fibrillation, but observational studies on the benefit–risk …

Objective To establish the risk of major bleeding in direct oral anticoagulant (DOAC) users
(overall and by class) versus vitamin K antagonist (VKA) users, using health care databases …

Aims We aimed to evaluate bleeding risk in clinical practice in patients with atrial fibrillation
(AF) being prescribed dabigatran, rivaroxaban, or apixaban compared with warfarin …

Background The benefit of direct oral anticoagulants (DOACs) versus vitamin K antagonists
(VKAs) on major bleeding was less prominent among atrial fibrillation (AF) patients with …

Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …

Aims There are conflicting signals in the literature about comparative safety and
effectiveness of direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) …

Aim Non‐vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …

Objective: To conduct a systematic literature review (SLR) and network meta-analysis (NMA)
of real-world studies comparing major bleeding risk among patients with non-valvular atrial …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

Aims The aim of this study was to compare the clinical effectiveness and safety of direct oral
anticoagulants (DOACs) in patients with atrial fibrillation (AF) in routine clinical practice …